A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease

Journal of Infectious Diseases

Volumn 188, Issue 5, 2003, Pages 625-634

  Fischl, Margaret A ^a   Ribaudo, Heather J ^b   Collier, Ann C ^c   Erice, Alejo ^d,l   Giuliano, Marina ^k   Dehlinger, Marjorie ^e   Eron Jr , Joseph J ^f   Saag, Michael S ^g   Hammer, Scott M ^h   Vella, Stefano ^k   Morse, Gene D ⁱ   Feinberg, Judith E ^j  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g University of Alabama at Birmingham   (United States)

^h Columbia Univ Coll of Phys/Surgs ^*  (United States)

ⁱ UNIVERSITY AT BUFFALO   (United States)

^j UNIVERSITY OF CINCINNATI   (United States)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l Hosp Asepeyo Serv de Med Intema   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; STAVUDINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BRAIN ARTERY ANEURYSM; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; KAPOSI SARCOMA; LEUKOENCEPHALOPATHY; LIVER DYSFUNCTION; LYMPHOMA; MALE; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TREATMENT FAILURE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; MALE; NELFINAVIR; OXAZINES; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0141612909     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377311     Document Type: Article

References (40)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency syndrome and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
4. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999; 180:659-65.
5. Paredes R, Puig T, Arnó A, et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive, protease inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr 1999; 22:132-8.
6. Morse GD. Drug interactions with antiretrovirals. In: Fischl M, Mandell G, eds. Update On AIDS. Curr Infect Dis Rep 2000; 2:257-66.
7. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000; 292:310-8.
8. Chiba M, Hensleigh M, Nishme JA, et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24:307-14.
9. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. National Institutes of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996; 124:1019-30.
10. Florida M, Bucciardini R, Ricciardulli D, et al. A randomized, double blind trial on the use of triple combination including nevirapine, a non-nucleoside reverse transcriptase inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:11-9.
11. Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm 1998; 55:233-54.
12. Riddler SA, Havlir D, Squires KE, et al. Coadministration of indinavir and nelfinavir human immunodeficiency virus type-1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrob Agents Chemother 2002; 46:3877-82.
13. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998; 36:2964-9.
14. Collier A, Ribaudo H, Feinberg J, Mukherjee L, Fischl M, Chesney M. Randomized study of telephone calls to improve adherence to antiretroviral therapy [poster 540-T]. ACTG Protocol 746 Team. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
15. DiCenzo R, Forrest A, Squires K, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Adult AIDS Clinical Trials Group Protocol 368/886 Study Team. Antimicrob Agents Chemother 2003; 47:1929-35.
16. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45:1086-93.
17. Yeh KC, Stone JA, Carides AD, Rolan P, Woolf E, Ju WD. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J Pharm Sci 1999; 88:568-73.
18. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan Adults. AIDS Res Hum Retroviruses 2000; 16:807-13.
19. D'Aquilla RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:92-6.
20. Petropoulos CJ, Parkin NT, Limoloi KJ, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 4:902-8.
21. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-63.
22. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-56.
23. Division of AIDS. Division of AIDS table for grading severity of adult adverse experiences. Rockville, MD: National Institute of Allergy, and Infectious Diseases, 1996.
24. Liang K-Y, Zeger SL. Longitudinal data analyses using generalized linear models. Biometrika 1986; 73:13-22.
25. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc Ser B 1972; 34:187-220.
26. Eron J, Junod P, Becker S, et al. NZT4002: 64-week analysis of combivir (COM)-based triple and quadruple therapy in antiretroviral-naive HIV-infected subjects [abstract WeOrB608]. In: Program and abstracts of the XIII International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, 2000.
27. Pakyz A, Israel DS, Monroe S, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000; 20:898-907.
28. Khaliq Y, Gallicano K, Seguin I, et al. Single- and multiple-dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000; 50:108-15.
29. deJong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type-infected person does not result in sustained suppression of viral replication. J Infect Dis 1997; 175:966-70.
30. Demeter LM, Meehan PM, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:136-44.
31. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-34.
32. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283:205-11.
33. Maguire M, Garland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14:1195-201.
34. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285:1155-63.
35. Erice A, Ribaudo H, Demeter L, et al. Antiretroviral resistance in ACTG 388 participants with virologic failure [poster 564-T]. ACTG 388 Resistance Study Team. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
36. Young B, Fischl MA, Wilson HM, et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 2002; 31:478-82.
37. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
38. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-73.
39. Rey D, Schmitt M-P, Partisani M, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001; 27:459-62.
40. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15:1517-26.